"The company selling a costly breakthrough to millions of hepatitis C sufferers thinks price is the wrong thing to talk about"
http://www.bloomberg.com/news/artic...osts-gilead-s-hepatitis-c-cures-spur-backlash
http://www.bloomberg.com/news/artic...osts-gilead-s-hepatitis-c-cures-spur-backlash